Twitxy Saved

Christina Yap

@ChristinaBYap

Professor of Clinical Trials Biostatistics. Group Leader Early Phase & Adaptive Trials. Interested in efficient trial designs & analysis @ICR_CTSU @ICR_London
England, United Kingdom icr.ac.uk/our-research/r… Joined November 2015
239 Following 813 Followers 358 Posts

Latest posts 5

Pinned post

Christina Yap @ChristinaBYap
Thank you for the kind invitation to share insights on the value of PROs in phase I dose-finding trials. A fantastic conference in the beautiful city of Barcelona - I’ve learnt so much too! Such a privilege to be part of it!
🩺 Phase 1 oncology trials focus on safety—but PROs can add real value. They complement clinician-reported dose-limiting toxicity (DLTs), offering a fuller view of treatment impact. Interest is growing across patients, researchers & regulators.
@ChristinaBYap @EORTC #QoLConf25
View quoted post on X
Christina Yap @ChristinaBYap
How about a two sequence (AB/BA) randomised blinded crossover design? PROs: Smaller sample size to achieve the same statistical power. Participants have the opportunity to try both durians & state their individual choice. (Well, I would love to be a participant of such a study!)
Sanjay Popat @DrSanjayPopat Dec 7, 2024
Discussing the optimal sample size needed to taste the difference between and high-end and standard durian. Should we be blinded? Any views on the design? #ESMOAsia24 @myESMO
View quoted post on X